januar 13, 2020
Cambridge, UK and Indianapolis, US – 13 January 2020: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 8,994,667 Ordinary Shares of...
First indication of human safety and pharmacokinetic profiles for SPR206 supports advancement of program to clinical pharmacology studies planned to initiate in the second half of 2020 CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 13 January 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”, the “Group”), (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces a...


Maude er blevet den stereotype migræne-patient – men det er ikke helt virkelighedsdækkende
31. juli 2020
Urgammelt DNA kaster en ’videnskabelig håndgranat’ ind i diskussionen om menneskets ankomst til Amerika
23. juli 2020
Danske forskere kortlægger central sygdomsmekanisme – og beskriver et helt nyt protein
20. juli 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge